İmmun checkpoint inhibitörleri ilişkili bağ dokusu hastalıkları

İmmün checkpoint inhibitörleri kanser tedavisinde kullanılan ve kullanımı gün geçtikçe artan ilaçlardır. Bu ilaçlarla hemen her organa ait immün ilişkili yan etkiler bildirilmiştir. Hepatit, kolit, pnömoni, döküntü, tiroidit, hipofizit en sık görülenlerdir. İmmün ilişkili yan etkiler genelde hafif-orta şiddette olup sıklığı %90’ının üzerinde bildirilmiştir. Romatolojik yan etkiler diğerlerine göre daha az bildirilmiş olmakla birlikte bu yan etkilerin gerçek sıklığı tam olarak bilinmemektedir. İmmün checkpoint inhibitörleri ile en sık bildirilen romatolojik yan etki artralji ve artrittir. Bunun dışında miyozit, sikka sendromu, skleroderma ve sarkoidoz ile ilişkili olgu bildirimleri de mevcuttur. Romatolojik yan etkiler konusunda farkındalığın artması bu olguların erken tanınması ve tedavisi açısından önemlidir.

Immune checkpoint inhibitors related connective tissue diseases

Immune checkpoint inhibitors are drugs that used in cancer treatment and increased in the use day by day. Immunerelated adverse events of almost any organs are reported with these drugs. Hepatitis, colitis, pneumonitis, rash, thyroiditis, hypophysitis are the most common. Immune-related adverse events are generally mild to moderate, with a frequency greater than 90%. Although the rheumatologic adverse events are reported less than others, the true incidence of these adverse events is not fully known. Arthralgia and arthritis are the most commonly reported rheumatic immune-related adverse events in immune checkpoint inhibitors. In addition, there are case reports related to myositis, sikka syndrome, scleroderma and sarcoidosis. Increased awareness of rheumatic adverse events is important for early diagnosis and treatment of these cases.

PDF

___

1. Calabrese L, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol 2018;14(10):569-79.

2. Pisetsky DS. Effects of immune checkpoint inhibitors on B cell: relationship to immune-related adverse events. Ann Rheum Dis 2018;77(6):795-6.

3. Cappelli LC, Shah AA, Bingham CO 3rd. Immune-related adverse effects of cancer immunotherapy-implications for rheumatology. Rheum Dis Clin North Am 2017;43(1):65-78.

4. Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occuring after immune checkpoint inhibitor treatment. Ann Rheum Dis 2017;76(10):1747-50.

5. Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer – clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2017;77(3):393-8.

6. Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients with immune checkpoint inhibitors. Autoimmun Rev 2018;17(3):284-9.

7. Tocut M, Brenner R, Znadman-Goddard. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018;17(6):610-6.

8. Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother 2018;67(2):175-182.

9. Naidoo J, Cappelli LC, Forde PM, et al. Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade. Oncologist 20017;22(6):627-30.

10. Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with antiprogrammed cell death 1/anti-programmed cell death-ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer 2017;82:34-44.

11. Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differ by immunotherapy regiment. Semin Arthritis Rheum 2018;48(3):553-7.

12. Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: Emerging immune-mediated myopathies. J Immunther 2018;41(4):208-11.